comment: front-line osimertinib significantly lengthens overall survival in egfr-mutation positi...
Published 4 years ago • 212 plays • Length 1:36Download video MP4
Download video MP3
Similar videos
-
5:06
front-line osimertinib significantly lengthens overall survival in egfr-mutation positive nsclc
-
2:20
osimertinib with chemotherapy in egfr-mutated nsclc | nejm
-
1:46
osimertinib after surgery significantly improves survival in resected egfr-mutated nsclc
-
5:26
first-line osimertinib in egfr mutant ansclc patients: progression pattern and safety in the rea...
-
17:55
front-line targeted therapy for advanced egfr-positive disease
-
2:21
osimertinib ipilimumab in egfr-mutated nsclc
-
2:20
osimertinib in advanced non–small-cell lung cancer
-
9:49
osimertinib as frontline therapy for egfr-positive nsclc
-
3:31
osimertinib plus gefitinib for treatment of egfr-mutated non-small cell lung cancer
-
6:51
osimertinib as frontline therapy in egfr-positive nsclc
-
1:45
phase iii data support frontline osimertinib in egfr-mutant lung cancers
-
6:43
sequential afatinib and osimertinib in egfr mutation-positive nsclc patients: updated results
-
6:20
asco 2023 highlights on adjuvant osimertinib in resected egfr mutated nsclc: the adaura trial
-
3:42
comment: osimertinib in egfr-mutation positive nsclc
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
6:30
osimertinib adjuvant therapy in patients with early stage egfr mutated nsclc after tumour resection
-
0:55
osimertinib for egfr-mutant lung cancer
-
8:44
flaura final analysis: osimertinib for first-line egfrm nsclc
-
5:18
frontline therapy for egfr plus nsclc: osimertinib’s impact